title: Intrathecal trastuzumab: dose matters.
authors.forename: Silvia
authors.initials: S
authors.lastname: Hofer
authors.forename: Karin
authors.initials: K
authors.lastname: Mengele
authors.forename: Hans Joachim
authors.initials: HJ
authors.lastname: Stemmler
authors.forename: Manfred
authors.initials: M
authors.lastname: Schmitt
authors.forename: Bernhard
authors.initials: B
authors.lastname: Pestalozzi
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid; D014408:Biomarkers, Tumor / Q000032:analysis*; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology*; D016371:Cranial Irradiation; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007278:Injections, Spinal; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D013129:Spinal Puncture; D000068878:Trastuzumab; D016896:Treatment Outcome; D015854:Up-Regulation
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human